What’s Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Upside After This Short Interest Decrease?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) registered a decrease of 16.07% in short interest. ADMS’s total short interest was 5.38 million shares in July as published by FINRA. Its down 16.07% from 6.41M shares, reported previously. With 497,400 shares average volume, it will take short sellers 11 days to cover their ADMS’s short positions. The short interest to Adamas Pharmaceuticals Inc’s float is 26.1%.

The stock increased 0.17% or $0.01 during the last trading session, reaching $6. About 173,158 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has declined 82.00% since July 14, 2018 and is downtrending. It has underperformed by 86.43% the S&P500.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $165.20 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 5 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Adamas Pharmaceuticals had 9 analyst reports since February 26, 2019 according to SRatingsIntel. Northland Capital maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Tuesday, March 5. Northland Capital has “Buy” rating and $28 target. Cowen & Co downgraded the shares of ADMS in report on Tuesday, March 5 to “Market Perform” rating. Piper Jaffray maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Tuesday, March 5. Piper Jaffray has “Buy” rating and $23 target. On Tuesday, March 5 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Tuesday, March 5, the company rating was downgraded by Mizuho.

More notable recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Seekingalpha.com which released: “Adamas Pharmaceuticals, Inc. (ADMS) CEO Gregory Went on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on May 09, 2019, also Benzinga.com with their article: “The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut – Benzinga” published on May 09, 2019, Globenewswire.com published: “Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRIâ„¢ Sales Results and Outlines Key Priorities for 2019 – GlobeNewswire” on January 06, 2019. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were released by: Globenewswire.com and their article: “Adamas Reports Third Quarter 2018 Financial Results Nasdaq:ADMS – GlobeNewswire” published on November 01, 2018 as well as Globenewswire.com‘s news article titled: “Bragar Eagel & Squire, PC is Investigating Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm – GlobeNewswire” with publication date: May 28, 2019.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.